These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38747643)

  • 1. How calcineurin inhibitors affect cognition.
    Thiankhaw K; Chattipakorn N; Chattipakorn SC
    Acta Physiol (Oxf); 2024 Jul; 240(7):e14161. PubMed ID: 38747643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.
    Eberhardt W; Nasrullah U; Pfeilschifter J
    Cell Signal; 2018 Dec; 52():1-11. PubMed ID: 30145216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer-like behavior and synaptic dysfunction in 3 × Tg-AD mice are reversed with calcineurin inhibition.
    Zeng J; Hu XF; Sun DS; Hong XY; Ma JZ; Feng Q
    Exp Brain Res; 2024 Jun; 242(6):1507-1515. PubMed ID: 38719948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive function after heart transplantation: Comparing everolimus-based and calcineurin inhibitor-based regimens.
    Bürker BS; Gullestad L; Gude E; Relbo Authen A; Grov I; Hol PK; Andreassen AK; Arora S; Dew MA; Fiane AE; Haraldsen IR; Malt UF; Andersson S
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28185318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tacrolimus on c-fos in hippocampus and memory performances in streptozotocin model of Alzheimer’s disease of rats.
    Köylü A; Altunkaynak BZ; Delibaş B
    Turk J Med Sci; 2021 Aug; 51(4):2159-2166. PubMed ID: 33754647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm calcineurin inhibitor therapy and brain function in patients after liver transplantation.
    Pflugrad H; Schrader AK; Tryc AB; Ding X; Lanfermann H; Jäckel E; Schrem H; Beneke J; Barg-Hock H; Klempnauer J; Weissenborn K
    Liver Transpl; 2018 Jan; 24(1):56-66. PubMed ID: 29156491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is It Time to Repurpose Calcineurin Inhibitors for the Treatment of Cognitive Impairment and Dementia?
    Norris CM
    J Alzheimers Dis; 2023; 95(2):599-602. PubMed ID: 37661889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.
    Schmitz B; Pflugrad H; Tryc AB; Lanfermann H; Jäckel E; Schrem H; Beneke J; Barg-Hock H; Klempnauer J; Weissenborn K; Ding XQ
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1431-1441. PubMed ID: 31006881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients.
    Lin W; Mou L; Tu H; Zhu L; Wang J; Chen J; Hu Y
    J Clin Pharm Ther; 2017 Feb; 42(1):122-124. PubMed ID: 27966241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin Inhibitors Nephrotoxicity Prevention Strategies With Stress on Belatacept-Based Rescue Immunotherapy: A Review of the Current Evidence.
    El Hennawy HM; Faifi ASA; El Nazer W; Mahedy A; Kamal A; Al Faifi IS; Abdulmalik H; Safar O; Zaitoun MF; Fahmy AE
    Transplant Proc; 2021 Jun; 53(5):1532-1540. PubMed ID: 34020797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zingiber officinale ameliorates Alzheimer's disease and Cognitive Impairments: Lessons from preclinical studies.
    Talebi M; İlgün S; Ebrahimi V; Talebi M; Farkhondeh T; Ebrahimi H; Samarghandian S
    Biomed Pharmacother; 2021 Jan; 133():111088. PubMed ID: 33378982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcineurin Inhibitor Toxicity in Solid Organ Transplantation.
    Karolin A; Genitsch V; Sidler D
    Pharmacology; 2021; 106(7-8):347-355. PubMed ID: 34130291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of immunosuppressive therapy as risk factor for complications after liver transplantation.
    De Simone P; Carrai P; Coletti L; Ghinolfi D; Petruccelli S; Filipponi F
    Best Pract Res Clin Gastroenterol; 2017 Apr; 31(2):199-209. PubMed ID: 28624108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Many Faces of Calcineurin Inhibitor Toxicity-What the FK?
    Farouk SS; Rein JL
    Adv Chronic Kidney Dis; 2020 Jan; 27(1):56-66. PubMed ID: 32147003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor sparing in paediatric solid organ transplantation : managing the efficacy/toxicity conundrum.
    Tredger JM; Brown NW; Dhawan A
    Drugs; 2008; 68(10):1385-414. PubMed ID: 18578558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CaN/NFAT in Alzheimer's brain degeneration.
    Mackiewicz J; Lisek M; Boczek T
    Front Immunol; 2023; 14():1281882. PubMed ID: 38077352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.